Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we ...

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report), with a price ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...